Clinical Efficacy Of Sorafenib Combined With TACE In The Treatment Of Middle And Advanced Hepatocellular Carcinoma

Purpose To investigate the efficacy and safety of sorafenib combined with transcatheter hepatic artery embolization in the treatment of patients with middle and advanced hepatocellular carcinoma.Methods Retrospectively analyzed the 44 patients with middle and advanced hepatocellular carcinoma in general hospital of ningxia medical university from june 2016 to june 2019,these patients were divided into two groups according to whether or not to treat solafeni after TACE—the experimental group(solafini combined with TACE group)and the control group(TACE group alone).In the experimental group,the time of oral solafeni was 3-7 days after transcatheter artery embolization,400 mg/time,BID.Follow-up every 3-6 weeks after TACE,patients were evaluated according to modified response evaluation criteria in solid tumors(mRECIST),the overall survival(OS),disease control rate(DCR),time to progression(TTP)and adverse reaction were compared respectively analyse the clinical efficacy and safety of sorafeni combined with TACE in the treatment of middle and advanced hepatocellular carcinoma.all the data were analyzed by spss19.0 statistical software,the sample mean of each group was compared with t test,the classification variables were used X~2 test,the survival time was calculated by kaplan-meier method,and the single factor analysis was performed by log-rank test.the test level?=0.05,and the difference was considered statistically significant by P?0.05.Results Solafenib combined with TACE was better than TACE alone in the treatment of middle and advanced liver cancer(DCR was 68.1%vs 36.4%,the difference was statistically significant P=0.035.The median survival was 17.6 vs 9.7 months,and the difference was statistically significant,P=0.002.The median disease progression period was 12.5 vs 7.4months,the difference was statistically significant,P=0.003.).patients in both groups had postoperative adverse reactions but sorafini did not increase the incidence of adverse reactions in tace and did not have cases of solafini-related adverse reaction death.Conclusions 1.Solafeni combined with TACE is safe and reliable for the treatment of advanced liver cancer,TACE combined with solafeni does not increase the adverse reaction of TACE.2.Solafini combined with TACE in the treatment of advanced liver cancer patients than simple TACE treatment can significantly increase the overall survival and disease control rate.